Paul Jones

Summary

Affiliation: St George's
Country: UK

Publications

  1. ncbi Activity limitation and quality of life in COPD
    Paul W Jones
    St George s, University of London, London, United Kingdom
    COPD 4:273-8. 2007
  2. doi Health status and the spiral of decline
    Paul W Jones
    St George s, University of London, Cranmer Terrace, London, UK
    COPD 6:59-63. 2009
  3. doi Characteristics of a COPD population categorised using the GOLD framework by health status and exacerbations
    Paul W Jones
    Clinical Science, St George s, University of London, London, United Kingdom Electronic address
    Respir Med 108:129-35. 2014
  4. doi Comparative efficacy of long-acting bronchodilators for COPD--a network meta-analysis
    Shannon Cope
    Division of Clinical Science, St George s University of London, London SW17 0RE, UK
    Respir Res 14:100. 2013
  5. doi Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review
    Paul Jones
    St George s University of London, Cranmer Terrace, London, SW17 0RE, UK
    Adv Ther 30:354-68. 2013
  6. pmc Beyond FEV₁ in COPD: a review of patient-reported outcomes and their measurement
    Paul Jones
    Division of Clinical Science, University of London, London, UK
    Int J Chron Obstruct Pulmon Dis 7:697-709. 2012
  7. ncbi Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study
    Paul W Jones
    St George s, University of London, Cranmer Terrace, London, SW17 0RE, UK
    Eur Respir J 40:830-6. 2012
  8. doi Tests of the responsiveness of the COPD assessment test following acute exacerbation and pulmonary rehabilitation
    Paul W Jones
    Division of Clinical Science, St George s University of London, London, England
    Chest 142:134-40. 2012
  9. pmc Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis
    Paul W Jones
    Division of Clinical Science, St George s, University of London, London, UK
    Respir Res 12:161. 2011
  10. pmc Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review
    Marie Westwood
    Kleijnen Systematic Reviews Ltd, York, UK
    Respir Res 12:40. 2011

Detail Information

Publications45

  1. ncbi Activity limitation and quality of life in COPD
    Paul W Jones
    St George s, University of London, London, United Kingdom
    COPD 4:273-8. 2007
    ..This suggests that self-reported limitation of activity may form a reliable construct, and may also provide a good surrogate marker of health status in COPD...
  2. doi Health status and the spiral of decline
    Paul W Jones
    St George s, University of London, Cranmer Terrace, London, UK
    COPD 6:59-63. 2009
    ..Inhaled corticosteroids have been shown to reduce the rate of decline of health status, possibly due to exacerbation prevention...
  3. doi Characteristics of a COPD population categorised using the GOLD framework by health status and exacerbations
    Paul W Jones
    Clinical Science, St George s, University of London, London, United Kingdom Electronic address
    Respir Med 108:129-35. 2014
    ..In patients seen in routine clinical settings, 25% of GOLD low risk patients had one exacerbation per year and the incidence of cardio-vascular and metabolic diseases increases with worsening GOLD group. ..
  4. doi Comparative efficacy of long-acting bronchodilators for COPD--a network meta-analysis
    Shannon Cope
    Division of Clinical Science, St George s University of London, London SW17 0RE, UK
    Respir Res 14:100. 2013
    ....
  5. doi Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review
    Paul Jones
    St George s University of London, Cranmer Terrace, London, SW17 0RE, UK
    Adv Ther 30:354-68. 2013
    ..i.d. is effective for the treatment of patients with COPD, offering improvements in lung function, breathlessness, and HRQoL, with a good safety profile and a low incidence of anticholinergic and cardiac AEs...
  6. pmc Beyond FEV₁ in COPD: a review of patient-reported outcomes and their measurement
    Paul Jones
    Division of Clinical Science, University of London, London, UK
    Int J Chron Obstruct Pulmon Dis 7:697-709. 2012
    ..In turn, this will help us to understand better the patient's experience of the disease...
  7. ncbi Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study
    Paul W Jones
    St George s, University of London, Cranmer Terrace, London, SW17 0RE, UK
    Eur Respir J 40:830-6. 2012
    ..Twice-daily aclidinium significantly improved bronchodilation, health status and dyspnoea, and was well tolerated in patients with COPD...
  8. doi Tests of the responsiveness of the COPD assessment test following acute exacerbation and pulmonary rehabilitation
    Paul W Jones
    Division of Clinical Science, St George s University of London, London, England
    Chest 142:134-40. 2012
    ..The COPD Assessment Test (CAT) is an eight-item questionnaire suitable for routine clinical use that shows reliability and validity in stable and exacerbating COPD...
  9. pmc Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis
    Paul W Jones
    Division of Clinical Science, St George s, University of London, London, UK
    Respir Res 12:161. 2011
    ..We examined whether changes in trough forced expiratory volume in 1 second (FEV(1)) are correlated with changes in patient-reported outcomes...
  10. pmc Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review
    Marie Westwood
    Kleijnen Systematic Reviews Ltd, York, UK
    Respir Res 12:40. 2011
    ..This systematic review and study-level analysis investigated the relationship between changes in FEV1 and changes in health status with bronchodilator therapy...
  11. pmc Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study
    Christine R Jenkins
    Woolcock Institute of Medical Research, Sydney, Australia
    Respir Res 10:59. 2009
    ..However, there are only limited data about the influence of GOLD severity staging on the effectiveness of SFC, particularly in patients with milder disease...
  12. pmc Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial
    Sanjay Sethi
    Division of Pulmonary, Critical Care and Sleep Medicine, University of Buffalo, State University of New York, Buffalo, NY, USA
    Respir Res 11:10. 2010
    ..This proof-of-concept study evaluates whether intermittent pulsed moxifloxacin treatment could reduce the frequency of these exacerbations...
  13. pmc Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease
    Paul W Jones
    St George s, University of London, London, UK
    Respir Res 12:55. 2011
    ..The long-term efficacy and safety of aclidinium bromide, a novel, long-acting muscarinic antagonist, were investigated in patients with moderate to severe chronic obstructive pulmonary disease (COPD)...
  14. pmc Health status in the TORCH study of COPD: treatment efficacy and other determinants of change
    Paul W Jones
    Department of Cardiac and Vascular Sciences, St George s Hospital, University of London, London, UK
    Respir Res 12:71. 2011
    ..Little is known about factors that determine health status decline in clinical trials of COPD...
  15. pmc Role of clinical questionnaires in optimizing everyday care of chronic obstructive pulmonary disease
    Paul W Jones
    Cardiac and Vascular Medicine, St George s, University of London, UK
    Int J Chron Obstruct Pulmon Dis 6:289-96. 2011
    ..Such questionnaires provide important measurements that can assist primary care physicians to capture the impact of COPD on patients' daily lives and wellbeing, and improve long-term COPD management...
  16. ncbi Quantifying of severity of exacerbations in chronic obstructive pulmonary disease: adaptations to the definition to allow quantification
    Paul Jones
    St George s, University of London, Cranmer Terrace, London, SW17 0RE, UK
    Proc Am Thorac Soc 4:597-601. 2007
    ..Methods for defining exacerbation onset and cessation are also proposed...
  17. ncbi Health status: what does it mean for payers and patients?
    Paul W Jones
    St George s, University of London, UK
    Proc Am Thorac Soc 3:222-6. 2006
    ..Improved health does not improve mortality or morbidity per se. It is also important to appreciate that the impact of any measured change in health may also be determined by the patient's baseline state...
  18. doi Improving the process and outcome of care in COPD: development of a standardised assessment tool
    Paul Jones
    Department of Cardiac and Vascular Sciences, St George s Hospital, University of London, London, UK
    Prim Care Respir J 18:208-15. 2009
    ..This goal requires regular systematic assessment of the patient's COPD with clear and efficient communication between the patient and clinician...
  19. pmc Creating scenarios of the impact of COPD and their relationship to COPD Assessment Test (CAT™) scores
    Paul W Jones
    Division of Clinical Science, St, George s University of London, London, UK
    BMC Pulm Med 11:42. 2011
    ..New questionnaires require reference points so that users can understand the scores; descriptive scenarios are one way of doing this. A novel method of creating scenarios is described...
  20. doi Development and first validation of the COPD Assessment Test
    P W Jones
    St George s University of London, UK
    Eur Respir J 34:648-54. 2009
    ..It has good measurement properties, is sensitive to differences in state and should provide a valid, reliable and standardised measure of COPD health status with worldwide relevance...
  21. doi Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD
    Paul W Jones
    Division of Clinical Science, St George s University of London, Cranmer Terrace, London SW17 0RE, UK
    Respir Med 105:892-9. 2011
    ..The aim of this paper is to assess the effect of indacaterol on dyspnoea and health status, using pooled study data to evaluate the relative efficacy of indacaterol and existing bronchodilators...
  22. ncbi Outcomes and markers in the assessment of chronic obstructive pulmonary disease
    P W Jones
    Respiratory Medicine, St George s, University of London, Cranmer Terrace, London, SW17 0RE, UK, and Serviei de Pneumologia, Hospital Universitari Son Dureta, Fundació Caubet CIMERA, Palma de Mallorca, Spain
    Eur Respir J 27:822-32. 2006
    ..The process of marker selection and validation is reviewed and potential new biological, physiological and symptomatic markers for chronic obstructive pulmonary disease are assessed...
  23. doi Efficacy of indacaterol in the treatment of patients with COPD
    Paul W Jones
    Division of Clinical Sciences, St George s University of London, London, UK
    Prim Care Respir J 20:380-8. 2011
    ..The safety profile was similar to placebo. Once-daily indacaterol is an effective and beneficial maintenance bronchodilator treatment for patients with moderate-to-severe COPD...
  24. ncbi Measuring the effects of COPD on the patient
    Paul Jones
    St George s Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK
    Respir Med 99:S11-8. 2005
    ..Future developments will include computerising these methodologies to permit faster and more individual patient-centred measurements...
  25. doi Predicting EQ-5D values using the SGRQ
    Helen J Starkie
    National Institute for Health and Clinical Excellence, London, UK
    Value Health 14:354-60. 2011
    ..George's Respiratory Questionnaire (SGRQ) in subjects with chronic obstructive pulmonary disease and to examine the effect of using this algorithm in predicting quality-adjusted life-years (QALYs)...
  26. ncbi Clinical effects of inhaled corticosteroids in chronic obstructive pulmonary disease
    Paul W Jones
    Respiratory Medicine, St George s Hospital Medical School, London SW 17 0RE, UK
    Proc Am Thorac Soc 1:167-70. 2004
    ..The effect of fluticasone on health appears to be due to a reduction in exacerbations coupled with its small effect on FEV(1)...
  27. doi Utility estimation in chronic obstructive pulmonary disease: a preference for change?
    Jennifer Petrillo
    Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK
    Pharmacoeconomics 29:917-32. 2011
    ..The trade-off allows relevant and sensitive matters most important to patients to be evaluated; however inevitable gaps such as those related to adverse events are not considered...
  28. ncbi The effect of helium and oxygen on exercise performance in chronic obstructive pulmonary disease: a randomized crossover trial
    Elizabeth A Laude
    Respiratory Medicine, Royal Hallamshire Hospital, Department of General Practice and Primary Care, ScHARR, Biomedical Sciences, University of Sheffield, Sheffield, UK
    Am J Respir Crit Care Med 173:865-70. 2006
    ..Replacing nitrogen with helium reduces expiratory flow resistance and may improve lung emptying. Combining these treatments should be independently effective...
  29. ncbi Development and Validation of an Improved, COPD-Specific Version of the St. George Respiratory Questionnaire
    Makiko Meguro
    Cardiac and Vascular Sciences, St George s, University of London, Cranmer Terrace, London, UK
    Chest 132:456-63. 2007
    ..To produce an improved, COPD-specific version of the St. George respiratory questionnaire (SGRQ-C)...
  30. pmc Novel study design to assess the utility of the copd assessment test in a primary care setting
    Kevin Gruffydd-Jones
    Respiratory Centre of Excellence, GlaxoSmithKline, London, United Kingdom
    BMC Med Res Methodol 13:63. 2013
    ..This paper discusses these challenges and the measures adopted to eliminate or minimise their impact on the study results...
  31. ncbi Adapting to asthma: are some asthma effects acceptable?
    Elizabeth A Barley
    Department of Medicine, Respiratory Medicine, Cardiac and Vascular Sciences, St George s, University of London, London, United Kingdom
    J Asthma 43:433-8. 2006
    ..We conclude that patients accept some asthma effects but do not appear to discount them when using a detailed health status questionnaire...
  32. ncbi Repeatability of a Rasch model of the AQ20 over five assessments
    Elizabeth A Barley
    Division of Physiological Medicine, Department of Medicine, St George s, University of London, Cranmer Terrace, SW17 0RE, London, UK
    Qual Life Res 15:801-9. 2006
    ..This is important as inclusion of 'time-dependent' items in a questionnaire may reduce the reliability of the instrument...
  33. ncbi Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis
    Robert Wilson
    Royal Brompton Hospital, London, UK
    Chest 125:953-64. 2004
    ..To compare the effectiveness of oral moxifloxacin with standard antibiotic therapy in acute exacerbation of chronic bronchitis (AECB)...
  34. ncbi St. George's Respiratory Questionnaire: MCID
    Paul W Jones
    St George s Hospital Medical School, London, UK
    COPD 2:75-9. 2005
    ....
  35. doi Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study
    Bartolome R Celli
    Tufts University School of Medicine, Pulmonary and Critical Care Division, Caritas St Elizabeth s Medical Center, Boston, MA 02135 2997, USA
    Am J Respir Crit Care Med 178:332-8. 2008
    ..Chronic obstructive pulmonary disease (COPD) is characterized by an accelerated decline in lung function. No drug has been shown conclusively to reduce this decline...
  36. pmc The severity of airways obstruction as a determinant of treatment response in COPD
    Peter Calverley
    Clinical Research Centre, University Hospital Aintree, Liverpool, UK
    Int J Chron Obstruct Pulmon Dis 1:209-18. 2006
    ....
  37. doi It's about time--directing our attention toward modifying the course of COPD
    Mario Cazzola
    University of Rome Tor Vergata, Department of Internal Medicine, Unit of Respiratory Diseases, Rome, Italy
    Respir Med 102:S37-48. 2008
    ..In this review we have considered three approaches toward modifying the course of COPD: smoking cessation, reduction in lung hyperinflation through medical and surgical approaches, and long-term pharmacotherapy...
  38. ncbi Brazilian version of airways questionnaire 20: a reproducibility study and correlations in patients with COPD
    Aquiles Camelier
    Pulmonary Division, Rehabilitation Center, Federal University of Sao Paulo, SP, Brazil
    Respir Med 99:602-8. 2005
    ..It can be concluded that AQ20 is reproducible, with an excellent correlation with SGRQ total score, and also having the advantage of taking just a few minutes to be applied and to have its score calculated...
  39. ncbi Evaluation of male COPD patients' health status by proxies
    Carme Santiveri
    Respiratory Department, Dos de Maig Hospital, Consorci Sanitari Integral, Barcelona 08025, Catalonia, Spain
    Respir Med 101:439-45. 2007
    ..The aim of this study was to analyse the reliability and validity of the St. George's Respiratory Questionnaire (SGRQ) answered by proxies and to determine their accuracy as raters...
  40. ncbi Health-related quality of life in patients with chronic respiratory failure after long-term mechanical ventilation
    Sara Euteneuer
    Krankenhaus Kloster Grafschaft, Schmallenberg, Germany
    Respir Med 100:477-86. 2006
    ..This study was aimed at assessing health-related quality of life (HRQL) in patients with chronic respiratory failure (CRF) and long-term survival following prolonged intensive care mechanical ventilation...
  41. ncbi Corticosteroid therapy in pulmonary sarcoidosis: a systematic review
    Shanthi Paramothayan
    Division of Physiological Medicine, St George s Hospital Medical School, Cranmer Terrace, London SW17 ORE, England
    JAMA 287:1301-7. 2002
    ..Spontaneous recovery is a common feature. Both the decision to initiate therapy and the treatment response may be influenced by disease severity, so trials need to use a randomized controlled design...
  42. doi Symptom measurement
    Paul W Jones
    Chest 134:226-7. 2008
  43. ncbi Measuring functional performance in patients with COPD: a discussion of patient-reported outcome measures
    Donald E Stull
    Center for Health Outcomes Research, United BioSource Corporation, Bethesda, MD, USA
    Curr Med Res Opin 23:2655-65. 2007
    ....
  44. ncbi Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease
    Peter M A Calverley
    University Hospital Aintree, Liverpool, United Kingdom
    N Engl J Med 356:775-89. 2007
    ..Long-acting beta-agonists and inhaled corticosteroids are used to treat chronic obstructive pulmonary disease (COPD), but their effect on survival is unknown...
  45. ncbi Withdrawal from treatment as an outcome in the ISOLDE study of COPD
    Peter M A Calverley
    Department of Medicine, University Hospital Aintree, Liverpool, United Kingdom
    Chest 124:1350-6. 2003
    ..To investigate the determinants of patient withdrawal from our study, and the effect of these withdrawals on the outcome of treatment with inhaled corticosteroids in patients with COPD...